Author:
Shimasaki Yukio,Sakaki Masashi,Itou Minoru,Kobayashi Tokurou,Aso Masako,Kagawa Tomoya,Saiki Takuya,Matsuno Kumi,Sano Yuhei,Shimizu Kohei,Kuroda Shingo,Koumura Emiko
Funder
Takeda Pharmaceuticals Ltd
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference16 articles.
1. Azizi M, Menard J. Renin inhibitors and cardiovascular and renal protection: an endless quest? Cardiovasc Drugs Ther. 2013;27:145–53.
2. Triller DM, Evang SD, Tadrous M, Yoo BK. First renin inhibitor, aliskiren, for the treatment of hypertension. Pharm World Sci. 2008;30:741–9.
3. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, Investigators AS. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433–46.
4. Imaeda Y, Tokuhara H, Fukase Y, et al. Discovery of TAK-272: A novel, potent, and orally active renin inhibitor. ACS Med Chem Lett. 2016;7:933–8.
5. Noden Pharma. Tekturna prescribing information. 2017.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210709s000lbl.pdf
. Accessed August 24, 2018